RU2017133990A - Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона - Google Patents
Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона Download PDFInfo
- Publication number
- RU2017133990A RU2017133990A RU2017133990A RU2017133990A RU2017133990A RU 2017133990 A RU2017133990 A RU 2017133990A RU 2017133990 A RU2017133990 A RU 2017133990A RU 2017133990 A RU2017133990 A RU 2017133990A RU 2017133990 A RU2017133990 A RU 2017133990A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- solid tablet
- amount
- drug content
- high drug
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 claims 54
- 239000002552 dosage form Substances 0.000 claims 53
- 229940079593 drug Drugs 0.000 claims 31
- 239000003814 drug Substances 0.000 claims 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 28
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 25
- 229940126601 medicinal product Drugs 0.000 claims 23
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 22
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 21
- 229960001681 croscarmellose sodium Drugs 0.000 claims 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 20
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 20
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 20
- 239000008108 microcrystalline cellulose Substances 0.000 claims 20
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 20
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 18
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 18
- 229960001507 ibrutinib Drugs 0.000 claims 18
- 239000008101 lactose Substances 0.000 claims 17
- 229960001375 lactose Drugs 0.000 claims 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 16
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 16
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 14
- 235000019359 magnesium stearate Nutrition 0.000 claims 14
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 10
- 239000003085 diluting agent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 239000008187 granular material Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 6
- 239000011230 binding agent Substances 0.000 claims 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 229920002472 Starch Polymers 0.000 claims 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 3
- -1 glidants Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- 229940057948 magnesium stearate Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 238000005550 wet granulation Methods 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 229960005168 croscarmellose Drugs 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 235000012239 silicon dioxide Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 229960001714 calcium phosphate Drugs 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 229940095672 calcium sulfate Drugs 0.000 claims 1
- 235000011132 calcium sulphate Nutrition 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229920006037 cross link polymer Polymers 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 229940096516 dextrates Drugs 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 229940080313 sodium starch Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127717P | 2015-03-03 | 2015-03-03 | |
| US62/127,717 | 2015-03-03 | ||
| US201562193518P | 2015-07-16 | 2015-07-16 | |
| US62/193,518 | 2015-07-16 | ||
| PCT/US2016/020467 WO2016141068A1 (en) | 2015-03-03 | 2016-03-02 | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022116422A Division RU2022116422A (ru) | 2015-03-03 | 2016-03-02 | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017133990A true RU2017133990A (ru) | 2019-04-05 |
| RU2017133990A3 RU2017133990A3 (enExample) | 2019-11-22 |
Family
ID=56848552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017133990A RU2017133990A (ru) | 2015-03-03 | 2016-03-02 | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US9655857B2 (enExample) |
| EP (2) | EP3265084B1 (enExample) |
| JP (3) | JP7149076B2 (enExample) |
| KR (2) | KR20250016514A (enExample) |
| CN (1) | CN107427498A (enExample) |
| AU (4) | AU2016226279B2 (enExample) |
| BR (2) | BR122023020985A2 (enExample) |
| CA (3) | CA3177995A1 (enExample) |
| DK (1) | DK3265084T3 (enExample) |
| ES (1) | ES2971597T3 (enExample) |
| FI (1) | FI3265084T3 (enExample) |
| HR (1) | HRP20240231T1 (enExample) |
| HU (1) | HUE065703T2 (enExample) |
| IL (3) | IL315294A (enExample) |
| LT (1) | LT3265084T (enExample) |
| MD (1) | MD3265084T2 (enExample) |
| MX (5) | MX394784B (enExample) |
| NZ (1) | NZ734446A (enExample) |
| PL (1) | PL3265084T3 (enExample) |
| PT (1) | PT3265084T (enExample) |
| RS (1) | RS65234B1 (enExample) |
| RU (1) | RU2017133990A (enExample) |
| SG (2) | SG10202102078VA (enExample) |
| SI (1) | SI3265084T1 (enExample) |
| SM (1) | SMT202400074T1 (enExample) |
| TW (5) | TWI810588B (enExample) |
| WO (1) | WO2016141068A1 (enExample) |
| ZA (1) | ZA201907661B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113343C (en) | 2010-06-03 | 2024-10-08 | Pharmacyclics Llc | USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA |
| KR20150015021A (ko) | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| KR102671643B1 (ko) | 2013-10-25 | 2024-05-31 | 파마싸이클릭스 엘엘씨 | 이식편 대 숙주 질환의 치료 및 예방 방법 |
| PH12020552048A1 (en) * | 2013-12-02 | 2022-05-11 | Pharmacyclics Llc | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| US9545407B2 (en) * | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| JP2018510156A (ja) | 2015-03-20 | 2018-04-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | アジュバントとしてｃｄ４０リガンドを有するワクチン |
| KR102632745B1 (ko) | 2015-04-06 | 2024-02-01 | 얀센 파마슈티카 엔브이 | 이브루티닙을 함유하는 조성물 |
| CN108472259A (zh) * | 2016-01-19 | 2018-08-31 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
| EP3523280A1 (en) | 2016-10-06 | 2019-08-14 | Janssen Pharmaceutica NV | Processes and intermediates for preparing a btk inhibitor |
| WO2018102725A1 (en) * | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| CN108653231A (zh) * | 2017-04-01 | 2018-10-16 | 北京赛林泰医药技术有限公司 | 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法 |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| CZ2017787A3 (cs) * | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| CA3089537A1 (en) * | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
| CN112584902A (zh) | 2018-05-03 | 2021-03-30 | 朱诺治疗学股份有限公司 | 嵌合抗原受体（car）t细胞疗法和激酶抑制剂的组合疗法 |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| EA202190045A1 (ru) | 2018-06-15 | 2021-03-17 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ибрутиниб |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| PE20212323A1 (es) * | 2019-02-22 | 2021-12-14 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas |
| CN118986983A (zh) | 2019-08-26 | 2024-11-22 | 阿尔维纳斯运营股份有限公司 | 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法 |
| US20210228479A1 (en) * | 2020-01-29 | 2021-07-29 | Farmakeio Nutraceuticals Llc | Steroidal compositions and method of making and use |
| KR20230107645A (ko) * | 2020-11-13 | 2023-07-17 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료에 사용하기 위한 정제 및 이의 제조 방법 |
| US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| TN2023000295A1 (en) * | 2021-06-10 | 2025-07-02 | Hikma Pharmaceuticals Usa Inc | Oral dosage forms of ibrutinib |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2025014827A1 (en) * | 2023-07-07 | 2025-01-16 | Acrotech Biopharma Inc. | Pralatrexate and cop combination for the treatment of patients with peripheral t cell lymphoma |
Family Cites Families (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| DE3303707A1 (de) | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
| EP0613373B1 (en) | 1991-11-22 | 2000-08-02 | THE PROCTER & GAMBLE PHARMACEUTICALS, INC. | Risedronate delayed-release compositions |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| EP0665010B1 (en) | 1992-10-16 | 2002-09-11 | Nippon Shinyaku Company, Limited | Method of manufacturing wax matrices |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| KR20000076426A (ko) | 1997-03-19 | 2000-12-26 | 스타르크, 카르크 | 피롤로[2,3-ｄ]피리미딘 및 티로신 키나제 저해제로서의 그의 용도 |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| JP3696087B2 (ja) | 1997-12-31 | 2005-09-14 | チョンワエ ファーマ コーポレーション | イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法 |
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| HUP0102661A2 (hu) | 1998-04-17 | 2001-11-28 | Parker Hughes Institute | BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk |
| US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
| US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| CA2385747A1 (en) | 1999-09-17 | 2001-03-22 | Gavin C. Hirst | Pyrazolopyrimidines as therapeutic agents |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| MXPA02003364A (es) | 1999-10-06 | 2002-08-23 | Boehringer Ingelheim Pharma | Compuestos heterociclicos utiles como inhibidores de las cinasas de tirosina. |
| JP2003516351A (ja) | 1999-11-30 | 2003-05-13 | パーカー ヒューズ インスティテュート | コラーゲン誘導血小板凝集阻害剤 |
| JP2003532632A (ja) | 1999-12-17 | 2003-11-05 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | 新規の複素環 |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| US20030040461A1 (en) | 2000-10-23 | 2003-02-27 | Mcatee C. Patrick | Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states |
| EP1345592A2 (en) | 2000-12-06 | 2003-09-24 | Pharmacia Corporation | Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
| WO2003000187A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
| WO2003014732A1 (en) | 2001-08-10 | 2003-02-20 | Symyx Technologies, Inc. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| US20040248906A1 (en) | 2001-08-10 | 2004-12-09 | Donato Nicholas J | Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia |
| WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
| WO2003046200A2 (en) | 2001-11-21 | 2003-06-05 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
| US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
| GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
| WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| US7687506B2 (en) | 2003-04-11 | 2010-03-30 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
| US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| EP1664762A4 (en) | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA |
| US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| WO2005037836A2 (en) | 2003-10-15 | 2005-04-28 | Osi Pharmaceuticals, Inc. | Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors |
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
| US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
| ATE383859T1 (de) | 2004-01-08 | 2008-02-15 | Wyeth Corp | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 |
| AU2005228845A1 (en) | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| ITMI20041314A1 (it) | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
| TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
| US20060079494A1 (en) | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| AU2005290028A1 (en) | 2004-09-28 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Substituted dipiperdine CCR2 antagonists |
| BRPI0517619A (pt) | 2004-11-10 | 2008-10-14 | Cgi Pharmaceuticals Inc | entidades quìmicas de imidazo[1,2-a] pirazin-8-ilaminas, suas composições farmacêuticas, uso dos referidos compostos na preparação de medicamento, processo de preparação de medicamento e métodos de utilização dos referidos compostos |
| GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
| US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
| AU2006223409B2 (en) | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| WO2006124462A2 (en) | 2005-05-13 | 2006-11-23 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
| EP2266974A1 (en) | 2005-05-23 | 2010-12-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts |
| PT1893612E (pt) | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Derivados de pirrolo [2,3-b]piridina como inibidores de proteína quinase |
| US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| EP1957491A2 (en) | 2005-11-12 | 2008-08-20 | Boehringer Ingelheim International GmbH | Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors |
| KR20080098490A (ko) | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
| ES2420834T3 (es) | 2006-01-30 | 2013-08-27 | The Scripps Research Institute | Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero |
| WO2007109604A2 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| KR20120051760A (ko) | 2006-04-04 | 2012-05-22 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| JP5682051B2 (ja) | 2006-05-18 | 2015-03-11 | ファーマサイクリックス，インク． | 細胞内キナーゼ阻害剤 |
| DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
| HUE028086T2 (en) | 2006-09-22 | 2016-11-28 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| ES2403546T3 (es) | 2006-11-03 | 2013-05-20 | Pharmacyclics, Inc. | Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización |
| FI20080352A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi |
| AU2008207986A1 (en) | 2007-01-22 | 2008-07-31 | Novavax, Inc. | Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability |
| NL2000640C2 (nl) | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2548558A1 (en) | 2007-03-28 | 2013-01-23 | Pharmacyclics, Inc. | Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| US20090010911A1 (en) | 2007-04-06 | 2009-01-08 | Iowa State University Research Foundation, Inc. | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities |
| TWI362930B (en) | 2007-04-27 | 2012-05-01 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
| AU2008282338B2 (en) | 2007-07-30 | 2015-02-12 | Ardea Biosciences, Inc. | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same |
| AU2008314632B2 (en) | 2007-10-19 | 2015-05-28 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| ES2444144T3 (es) | 2007-10-23 | 2014-02-24 | F. Hoffmann-La Roche Ag | Nuevos inhibidores de quinasa |
| US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
| US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP3090743A1 (en) | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| WO2009124982A1 (en) | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
| KR20110014149A (ko) | 2008-04-14 | 2011-02-10 | 아디아 바이오사이언스즈 인크. | 조성물 및 이것의 제조 및 사용 방법 |
| EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
| WO2010014728A1 (en) | 2008-07-29 | 2010-02-04 | Frontier Scientific Inc. | Use of tetrakis (n-alkylpyridinium) -porphyrin derivatives for killing microbes or preventing growth |
| JP5461565B2 (ja) * | 2008-10-09 | 2014-04-02 | アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ | 有機溶媒を使用したモキシフロキサシンの湿式造粒法 |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| JP5656976B2 (ja) | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| CN102713618B (zh) | 2009-09-16 | 2015-07-15 | 新基阿维罗米克斯研究公司 | 蛋白激酶复合物和抑制剂 |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| CN102918040B (zh) | 2010-05-31 | 2015-03-18 | 小野药品工业株式会社 | 6-羟基嘌呤衍生物 |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CA3113343C (en) | 2010-06-03 | 2024-10-08 | Pharmacyclics Llc | USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA |
| CN105061438B (zh) | 2010-06-23 | 2017-07-04 | 韩美科学株式会社 | 用于抑制酪氨酸激酶活性的稠合嘧啶衍生物 |
| EP2603081B1 (en) | 2010-08-10 | 2016-10-05 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
| BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| US8541391B2 (en) | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
| US8501484B2 (en) | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
| MX2011004759A (es) | 2011-05-04 | 2012-11-21 | Senosiain S A De C V Lab | Nuevas formas solidas de antibioticos. |
| HUE033019T2 (en) | 2011-05-17 | 2017-11-28 | Principia Biopharma Inc | Tyrosine kinase inhibitors |
| BR112014001440A2 (pt) * | 2011-07-18 | 2017-02-21 | Tokai Pharmaceuticals Inc | novas composições e métodos para o tratamento de câncer de próstata |
| PL3196202T3 (pl) | 2011-09-02 | 2019-09-30 | Incyte Holdings Corporation | Heterocykloaminy jako inhibitory pi3k |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| ES2946549T3 (es) | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Composición farmacéutica de nilotinib |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| JP5514256B2 (ja) | 2012-05-18 | 2014-06-04 | 株式会社東芝 | 磁気記憶素子及びその製造方法 |
| KR20150015021A (ko) | 2012-06-04 | 2015-02-09 | 파마시클릭스, 인코포레이티드 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| CN103121999A (zh) | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| EA201591656A1 (ru) | 2013-04-08 | 2016-05-31 | Фармасайкликс Элэлси | Комбинированная терапия с ибрутинибом |
| AU2014273946B2 (en) | 2013-05-30 | 2020-03-12 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| US20160067241A1 (en) | 2013-06-13 | 2016-03-10 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
| US10253244B2 (en) | 2013-09-04 | 2019-04-09 | Halliburton Energy Services, Inc. | Scale-inhibiting cocrystals for treatment of a subterranean formation |
| EP3044338B1 (en) | 2013-09-12 | 2021-11-24 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| CN104447701B (zh) | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
| CN105848680A (zh) | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | 使用布鲁顿酪氨酸激酶抑制剂和免疫疗法的治疗 |
| WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
| US20160310417A1 (en) | 2013-12-20 | 2016-10-27 | Emory University | Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents |
| CN103923084B (zh) | 2014-01-29 | 2016-08-17 | 苏州晶云药物科技有限公司 | 几种晶型及其制备方法 |
| EP3102190A4 (en) | 2014-02-07 | 2017-09-06 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
| US20150231077A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
| US20150238490A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
| US20150267752A1 (en) | 2014-03-19 | 2015-09-24 | Roller Bearing Company Of America, Inc. | Bearing outer race having a radially inwardly biased seal |
| JP2017509336A (ja) | 2014-03-20 | 2017-04-06 | ファーマサイクリックス エルエルシー | ホスホリパーゼｃガンマ２及び耐性に関連した変異 |
| AU2015237744A1 (en) | 2014-03-27 | 2016-09-15 | Wavelength Enterprises Ltd | Ibrutinib solid forms and production process therefor |
| CN105085529A (zh) | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
| US9127069B1 (en) * | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
| US20150110871A1 (en) | 2014-06-02 | 2015-04-23 | David Wong | Gastric retentive tablet compositions |
| WO2016007617A2 (en) | 2014-07-09 | 2016-01-14 | Novotec Consulting, Llc. | Pharmaceutical compounding kit |
| PT107846B (pt) | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
| WO2016020697A1 (en) | 2014-08-06 | 2016-02-11 | Cipla Limited | Pharmaceutical compositions of polymeric nanoparticles |
| US9545407B2 (en) * | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| WO2016025720A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
| ES2727952T3 (es) | 2014-10-01 | 2019-10-21 | Ratiopharm Gmbh | Sal de adición de ácido de ibrutinib |
| CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
| CN105640961A (zh) | 2014-11-18 | 2016-06-08 | 山东瑞禾医药科技有限公司 | 一种含依鲁替尼的药物组合物 |
| WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
| US20150224060A1 (en) | 2015-01-03 | 2015-08-13 | David Wong | Gastric retentive tablet compositions |
| CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
| WO2016139588A1 (en) | 2015-03-03 | 2016-09-09 | Dr. Reddy's Laboratories Limited | Polymorphs of ibrutinib |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| MA41827A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
| MA41828A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
| EP3524606A1 (en) | 2015-04-02 | 2019-08-14 | ratiopharm GmbH | Co-crystals of ibrutinib with carboxylic acids |
| KR102632745B1 (ko) | 2015-04-06 | 2024-02-01 | 얀센 파마슈티카 엔브이 | 이브루티닙을 함유하는 조성물 |
| CN105294696A (zh) | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
| CN105440040B (zh) | 2015-12-23 | 2018-03-13 | 浙江京新药业股份有限公司 | 依鲁替尼的纯化方法 |
| LT3405178T (lt) * | 2016-01-19 | 2025-11-10 | Formuluotės / kompozicijos, apimančios btk inhibitorių | |
| CN108472259A (zh) * | 2016-01-19 | 2018-08-31 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
| CN105646484A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 晶型b及制备方法 |
| CN105646499A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型g及制备方法 |
| CN105646498A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
| CN106619643A (zh) | 2016-11-11 | 2017-05-10 | 上海雅本化学有限公司 | 一种含依鲁替尼的药物组合物 |
-
2016
- 2016-03-01 IL IL315294A patent/IL315294A/en unknown
- 2016-03-02 HR HRP20240231TT patent/HRP20240231T1/hr unknown
- 2016-03-02 WO PCT/US2016/020467 patent/WO2016141068A1/en not_active Ceased
- 2016-03-02 NZ NZ734446A patent/NZ734446A/en unknown
- 2016-03-02 KR KR1020257002285A patent/KR20250016514A/ko active Pending
- 2016-03-02 CN CN201680016710.0A patent/CN107427498A/zh active Pending
- 2016-03-02 BR BR122023020985-0A patent/BR122023020985A2/pt not_active Application Discontinuation
- 2016-03-02 AU AU2016226279A patent/AU2016226279B2/en active Active
- 2016-03-02 TW TW110121912A patent/TWI810588B/zh active
- 2016-03-02 BR BR112017018931A patent/BR112017018931A2/pt not_active Application Discontinuation
- 2016-03-02 SG SG10202102078VA patent/SG10202102078VA/en unknown
- 2016-03-02 HU HUE16759417A patent/HUE065703T2/hu unknown
- 2016-03-02 MX MX2017011270A patent/MX394784B/es unknown
- 2016-03-02 CA CA3177995A patent/CA3177995A1/en active Pending
- 2016-03-02 PL PL16759417.5T patent/PL3265084T3/pl unknown
- 2016-03-02 CA CA3177990A patent/CA3177990A1/en active Pending
- 2016-03-02 SM SM20240074T patent/SMT202400074T1/it unknown
- 2016-03-02 TW TW112127725A patent/TW202419091A/zh unknown
- 2016-03-02 KR KR1020177026712A patent/KR20170122220A/ko not_active Ceased
- 2016-03-02 SI SI201631803T patent/SI3265084T1/sl unknown
- 2016-03-02 JP JP2017541753A patent/JP7149076B2/ja active Active
- 2016-03-02 RS RS20240214A patent/RS65234B1/sr unknown
- 2016-03-02 FI FIEP16759417.5T patent/FI3265084T3/fi active
- 2016-03-02 TW TW107118387A patent/TWI733027B/zh active
- 2016-03-02 DK DK16759417.5T patent/DK3265084T3/da active
- 2016-03-02 TW TW105106446A patent/TWI632912B/zh active
- 2016-03-02 LT LTEPPCT/US2016/020467T patent/LT3265084T/lt unknown
- 2016-03-02 TW TW111131798A patent/TW202315634A/zh unknown
- 2016-03-02 IL IL293284A patent/IL293284A/en unknown
- 2016-03-02 MD MDE20180058T patent/MD3265084T2/ro unknown
- 2016-03-02 CA CA2976695A patent/CA2976695C/en active Active
- 2016-03-02 EP EP16759417.5A patent/EP3265084B1/en active Active
- 2016-03-02 SG SG11201707122QA patent/SG11201707122QA/en unknown
- 2016-03-02 EP EP23211155.9A patent/EP4338738A3/en active Pending
- 2016-03-02 RU RU2017133990A patent/RU2017133990A/ru unknown
- 2016-03-02 PT PT167594175T patent/PT3265084T/pt unknown
- 2016-03-02 ES ES16759417T patent/ES2971597T3/es active Active
- 2016-03-03 US US15/060,010 patent/US9655857B2/en active Active
-
2017
- 2017-03-23 US US15/467,414 patent/US20170258729A1/en not_active Abandoned
- 2017-08-15 IL IL253995A patent/IL253995B1/en unknown
- 2017-09-04 MX MX2021015408A patent/MX2021015408A/es unknown
- 2017-09-04 MX MX2021015370A patent/MX2021015370A/es unknown
- 2017-09-04 MX MX2021015405A patent/MX2021015405A/es unknown
- 2017-09-04 MX MX2021015368A patent/MX2021015368A/es unknown
-
2018
- 2018-03-01 US US15/909,779 patent/US10010507B1/en active Active
- 2018-05-03 US US15/970,721 patent/US10213386B2/en active Active
- 2018-09-11 US US16/128,312 patent/US20190015340A1/en not_active Abandoned
- 2018-12-20 US US16/228,682 patent/US20190117579A1/en not_active Abandoned
-
2019
- 2019-11-19 ZA ZA2019/07661A patent/ZA201907661B/en unknown
-
2020
- 2020-04-10 US US16/846,064 patent/US10828259B2/en active Active
-
2021
- 2021-09-30 AU AU2021240244A patent/AU2021240244B2/en active Active
- 2021-11-29 US US17/536,701 patent/US20220331252A1/en not_active Abandoned
-
2022
- 2022-06-30 JP JP2022106400A patent/JP2022141701A/ja active Pending
-
2023
- 2023-05-01 AU AU2023202671A patent/AU2023202671B2/en active Active
-
2024
- 2024-08-05 JP JP2024129576A patent/JP2024170405A/ja active Pending
-
2025
- 2025-04-07 US US19/172,172 patent/US20250228783A1/en active Pending
- 2025-06-11 AU AU2025204331A patent/AU2025204331A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017133990A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| ES2197351T3 (es) | Granulado para la preparacion de composiciones de rapida desintegracion y disolucion que contiene una elevada cantidad de farmaco. | |
| KR102803917B1 (ko) | 루카파립의 고 용량 강도 정제 | |
| RU2017106795A (ru) | Новые составы ингибитора тирозинкиназы брутона | |
| KR100634253B1 (ko) | 초강력 붕해제를 사용한 고속-용해 에파비렌즈 캡슐 또는정제 및 그의 제조 방법 | |
| AU712464B2 (en) | Improvements in or relating to organic compositions | |
| JP2013530952A5 (enExample) | ||
| ME01442B (me) | Tabletna formulacija sa produženim otpuštanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatuivu so, postupak za proizvodnju iste i njena primjena | |
| JP2017525712A5 (enExample) | ||
| RU2006133902A (ru) | Твердые препаративные формы оспемифена | |
| CN101829125B (zh) | 用于防治骨关节痛的复方组合制剂及其制备方法 | |
| RU2012157256A (ru) | Фармацевтические композиции сокристаллов трамадола и коксибов | |
| JP2014237658A5 (enExample) | ||
| JP2004532863A5 (enExample) | ||
| JP2007523210A5 (enExample) | ||
| RU2005138496A (ru) | Фармацевтические композиции, включающие аторвастатин, изготовленный без гранулирования | |
| RU2009103658A (ru) | Фармацевтические композиции мемантина | |
| RU2019132494A (ru) | Фармацевтические таблетки с элтромбопагом оламина | |
| JP2009526840A (ja) | 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法 | |
| JP2015521191A5 (enExample) | ||
| RU2016106328A (ru) | Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления | |
| Kumar et al. | Development and characterization of melt-in-mouth tablets of haloperidol by sublimation technique | |
| EA201190091A1 (ru) | Активируемый влагой способ грануляции | |
| RU2022116422A (ru) | Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона | |
| Vishnu et al. | Comparison of disintegrant-addition methods on the compounding of orodispersible tablets |